Best of cardiology in 2024 : Check it out and find the winner.
January 1, 2025 by dr s venkatesan
Welcome to 2025 and best wishes for a great academic journey to all readers .

Collected from ACC website (Arranged in three heading) These are the creamy academic extract of whatever happened over the last one year. Thanks to ACC for compiling it. While the first one,(Trials) will be under scrutiny, the other two , ie the cardiology news stories and magazine reviews are absolute gem of learning resource.
Top 10 Clinical Trials
- Preventive PCI on Stenosis With Functionally Insignificant Vulnerable Plaque – PREVENT (ACC.24)
- Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With HF – FINEARTS-HF (ESC Congress 2024 and AHA 2024)
- Randomized Evaluation of Decreased Usage of Beta-Blockers After AMI – REDUCE-AMI (ACC.24)
- Microaxial Flow Pump in Infarct-Related Cardiogenic Shock – DanGer Shock (ACC.24)
- One-Month Ticagrelor Monotherapy After PCI in ACS – IVUS-ACS/ULTIMATE-DAPT (ACC.24 and TCT 2024)
- Colchicine in AMI – CLEAR SYNERGY (OASIS 9) (TCT 2024 and AHA 2024)
- Semaglutide Treatment Effect in People With Obesity and HFpEF and Diabetes Mellitus – STEP-HFpEF DM (ACC.24)
- Older Patients With NSTEMI Randomized Interventional Treatment – SENIOR-RITA (ESC Congress 2024)
- Assessment of Beta-Blocker Interruption 1 Year After an Uncomplicated MI on Safety and Symptomatic Cardiac Events Requiring Hospitalization – ABYSS (ESC Congress 2024)
- Study to Evaluate the Effect of Empagliflozin on Hospitalization For HF and Mortality in Patients With AMI – EMPACT-MI (ACC.24)
Top 10 ACC News Stories
- ACC, AHA Release New Perioperative Guideline For Patients Undergoing Noncardiac Surgery
- New ACC/AHA Guideline on Management of Lower Extremity PAD
- New ACC/AHA Guideline on Evaluation and Management of People With HCM
- New ACC Expert Consensus Decision Pathway Updates Guidance on HFrEF Management
- ACC Issues Guidance on HF Management, Treatment
- ACC Issues Guidance For Diagnosing and Managing Myocarditis
- ACC Issues Guidance on Arrhythmia Monitoring After Stroke
- ACC/AHA Add 9 New Performance and Quality Measures to Updated 2024 HF Measure Set
- ACC, AHA Release First-Ever Performance and Quality Measures For VHD and SHD
- 2025 Medicare Physician Fee Schedule Final Rule Deep Dive
Top 10 Cardiology Magazine Articles
- Cardiac Amyloidosis and How to Stop Missing the Diagnosis
- Acute Coronary Syndromes: New Perspectives, New Data
- HF in Women: Understanding the Differences to Change the Paradigm
- Navigating AFib Care Across the Continuum: Insights From the Guideline
- Takotsubo Syndrome: Expanding Insights, Unanswered Questions
- Clinical Decision-Making in Aortic Stenosis in Patients With Bicuspid Valves
- Rethinking the Meaning of IHD: Invasive Assessment of ANOCA
- Renal Denervation: Expanding Care For Treatment-Resistant HTN
- Cardiopsychology: Exploring the Heart/Brain Connection in Cardiovascular Disease
- Hypertrophic Septum: Ablation, Transcatheter Myotomy or Medical Therapy?
What happened to top 10 cardiology research papers of 2023 ? Did we follow up ? what is the Impact of them in the bed side ?
For some reason, we have a strong belief , that randomized control trials (RCT) are the only way science can express itself and move forward . This is a much more sacred rule in cardiology. In that sense, every year, we see more than 100s of RCT get released various research centers with varying credibility. If every RCT is taken at its face value, we should have conquered much of cardiology secrets long ago. Fortunately, that is not the case.
As an Intelligent, interventional cardiologists we are extremely talented (From tackling a left main dissection, to recapture a runaway TAVI and reimplant it ) .But, we have to admit, many (?most) of us lack the expertise of picking the genuine , winning research especially in the arena of new drugs and devices. Some times, I wonder, whether we have sort of outsourced the job of interpreting the results to invisible third parties. No escape from this ,this is the way science has to grow.
Final message : One study from 2024 really bothers
The PREVENT trial of 2024 is suggesting a tectonic shift in the way we should manage CAD. It is asking for stenting all non-flow limiting lesion , if found, to carry high risk plaques by intracoronary Imaging. We have a come full circle, from vulnerable plaque to vulnerable patient and let us hope, we do not become a vulnerable cardiologist.
Posted in Uncategorized |
- The Renal Warrior Project. Join Now
- Source: https://drsvenkatesan.com/2025/01/01/best-of-cardiology-in-2024-check-it-out-and-find-the-winner/